KR20230136693A - 2-플루오로-n-메틸-4-[7-(퀴놀린-6-일메틸)이미다조[1,2-b][1,2,4]트리아진-2-일]벤즈아미드의 정제 제제 - Google Patents

2-플루오로-n-메틸-4-[7-(퀴놀린-6-일메틸)이미다조[1,2-b][1,2,4]트리아진-2-일]벤즈아미드의 정제 제제 Download PDF

Info

Publication number
KR20230136693A
KR20230136693A KR1020237031767A KR20237031767A KR20230136693A KR 20230136693 A KR20230136693 A KR 20230136693A KR 1020237031767 A KR1020237031767 A KR 1020237031767A KR 20237031767 A KR20237031767 A KR 20237031767A KR 20230136693 A KR20230136693 A KR 20230136693A
Authority
KR
South Korea
Prior art keywords
fluoro
methyl
quinolin
imidazo
ylmethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020237031767A
Other languages
English (en)
Korean (ko)
Inventor
엘리자베트 곤칼베스
크리스틴 토치만
샤우-퐁 옌
수드하 비파군타
지신 종
Original Assignee
노파르티스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53762251&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20230136693(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 노파르티스 아게 filed Critical 노파르티스 아게
Publication of KR20230136693A publication Critical patent/KR20230136693A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/10—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/06—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of pills, lozenges or dragees
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020237031767A 2014-07-25 2015-07-22 2-플루오로-n-메틸-4-[7-(퀴놀린-6-일메틸)이미다조[1,2-b][1,2,4]트리아진-2-일]벤즈아미드의 정제 제제 Ceased KR20230136693A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462028865P 2014-07-25 2014-07-25
US62/028,865 2014-07-25
KR1020177004939A KR102581121B1 (ko) 2014-07-25 2015-07-22 2-플루오로-n-메틸-4-[7-(퀴놀린-6-일메틸)이미다조[1,2-b][1,2,4]트리아진-2-일]벤즈아미드의 정제 제제
PCT/IB2015/055561 WO2016012963A1 (en) 2014-07-25 2015-07-22 Tablet formulation of 2-fluoro-n-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020177004939A Division KR102581121B1 (ko) 2014-07-25 2015-07-22 2-플루오로-n-메틸-4-[7-(퀴놀린-6-일메틸)이미다조[1,2-b][1,2,4]트리아진-2-일]벤즈아미드의 정제 제제

Publications (1)

Publication Number Publication Date
KR20230136693A true KR20230136693A (ko) 2023-09-26

Family

ID=53762251

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020237031767A Ceased KR20230136693A (ko) 2014-07-25 2015-07-22 2-플루오로-n-메틸-4-[7-(퀴놀린-6-일메틸)이미다조[1,2-b][1,2,4]트리아진-2-일]벤즈아미드의 정제 제제
KR1020177004939A Active KR102581121B1 (ko) 2014-07-25 2015-07-22 2-플루오로-n-메틸-4-[7-(퀴놀린-6-일메틸)이미다조[1,2-b][1,2,4]트리아진-2-일]벤즈아미드의 정제 제제

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020177004939A Active KR102581121B1 (ko) 2014-07-25 2015-07-22 2-플루오로-n-메틸-4-[7-(퀴놀린-6-일메틸)이미다조[1,2-b][1,2,4]트리아진-2-일]벤즈아미드의 정제 제제

Country Status (31)

Country Link
US (5) US10085993B2 (enExample)
EP (2) EP3848376A1 (enExample)
JP (3) JP6770946B2 (enExample)
KR (2) KR20230136693A (enExample)
CN (2) CN115364061A (enExample)
AR (1) AR101286A1 (enExample)
AU (4) AU2015293539A1 (enExample)
CA (1) CA2954840A1 (enExample)
CL (1) CL2017000180A1 (enExample)
CO (1) CO2017000586A2 (enExample)
DK (1) DK3172209T3 (enExample)
EA (2) EA039220B1 (enExample)
EC (1) ECSP17011672A (enExample)
ES (1) ES2857523T3 (enExample)
FR (1) FR22C1058I2 (enExample)
GT (1) GT201700007A (enExample)
HU (2) HUE053346T2 (enExample)
IL (1) IL250166B (enExample)
JO (1) JO3618B1 (enExample)
MX (2) MX379279B (enExample)
MY (1) MY187276A (enExample)
NL (1) NL301208I2 (enExample)
NO (1) NO2022058I1 (enExample)
PE (1) PE20170523A1 (enExample)
PH (1) PH12017500121A1 (enExample)
PL (1) PL3172209T3 (enExample)
PT (1) PT3172209T (enExample)
SG (2) SG11201700147SA (enExample)
SI (1) SI3172209T1 (enExample)
TW (2) TW202200148A (enExample)
WO (1) WO2016012963A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2868202C (en) 2012-04-03 2021-08-10 Novartis Ag Combination products with tyrosine kinase inhibitors and their use
DK3172209T3 (da) 2014-07-25 2021-02-22 Novartis Ag Tabletformulering med 2-fluor-n-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamid
TWI736660B (zh) 2016-08-10 2021-08-21 瑞士商赫孚孟拉羅股份公司 包含Akt蛋白質激酶抑制劑之醫藥組合物
US11407735B2 (en) 2019-05-16 2022-08-09 Novartis Ag Crystalline forms of N-[4-(Chlorodifluoromethoxy)phenyl]-6-[(3R)-3-hydroxypyrrolidin-1-yl]-5-(1H-pyrazol-5-yl)pyridine-3-carboxamide
JP7675071B2 (ja) * 2019-10-24 2025-05-12 ハンミ ファーマシューティカル カンパニー リミテッド がん細胞の成長を阻害するアミド誘導体を含む医薬調製物およびそれを含有する医薬品
WO2022007752A1 (zh) * 2020-07-06 2022-01-13 苏州晶云药物科技股份有限公司 苯甲酰胺类化合物及其二盐酸盐的新晶型及其制备方法
CN114853762A (zh) * 2021-02-03 2022-08-05 四川科伦药物研究院有限公司 一种咪唑并三嗪类化合物的固体形式及其制备方法和用途
CN118251220A (zh) * 2022-01-19 2024-06-25 江苏奥赛康药业有限公司 一种包含嘧啶基团的三并环类化合物的组合物及其制备方法和应用
WO2023249994A1 (en) * 2022-06-22 2023-12-28 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
AU2023324893A1 (en) * 2022-08-19 2025-03-13 Mirati Therapeutics, Inc. Adagrasib solid pharmaceutical compositions
WO2024206858A1 (en) 2023-03-30 2024-10-03 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof
AU2024265078A1 (en) 2023-05-04 2025-12-11 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6762778B1 (en) 1999-06-10 2004-07-13 Dassault Systemes Three dimensional graphical manipulator
CA2465565A1 (en) * 2003-06-12 2004-12-12 Warner-Lambert Company Llc Pharmaceutical compositions of atorvastatin
EP1909777A2 (en) * 2005-07-22 2008-04-16 Myriad Genetics, Inc. High drug load formulations and dosage forms
WO2007031933A2 (en) 2005-09-12 2007-03-22 Actelion Pharmaceuticals Ltd Stable pharmaceutical composition comprising a pyrimidine-sulfamide
CA2563690C (en) 2006-10-12 2014-10-07 Pharmascience Inc. Pharmaceutical compositions comprising intra- and extra- granular fractions
PL2497470T3 (pl) 2006-11-22 2016-04-29 Incyte Holdings Corp Imidazotriazyny i imidazopirymidyny jako inhibitory kinazy
JP6022158B2 (ja) 2008-05-21 2016-11-09 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ ２−フルオロ−Ｎ−メチル−４−［７−（キノリン−６−イル−メチル）−イミダゾ［１，２−ｂ］［１，２，４］トリアジン−２−イル］ベンズアミドの塩及びそれを調製することに関する方法
PT4066821T (pt) * 2009-11-09 2025-06-03 Wyeth Llc Formulações de comprimidos de maleato de neratinib
JP5846647B2 (ja) 2010-02-25 2016-01-20 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ アピキサバン製剤
NZ603686A (en) * 2010-05-21 2014-11-28 Incyte Corp Topical formulation for a jak inhibitor
WO2012006298A2 (en) 2010-07-06 2012-01-12 Janssen Pharmaceutica Nv Formulation for co-therapy treatment of diabetes
RU2705095C2 (ru) 2012-08-16 2019-11-05 Новартис Аг Комбинация ингибитора pik3 и ингибитора с-мет
DK3172209T3 (da) 2014-07-25 2021-02-22 Novartis Ag Tabletformulering med 2-fluor-n-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamid

Also Published As

Publication number Publication date
MY187276A (en) 2021-09-17
US10596178B2 (en) 2020-03-24
FR22C1058I1 (fr) 2023-01-06
CL2017000180A1 (es) 2017-09-15
KR20170039211A (ko) 2017-04-10
EA201790259A1 (ru) 2017-06-30
ECSP17011672A (es) 2018-03-31
SG11201700147SA (en) 2017-02-27
AU2021202500A1 (en) 2021-05-20
US20210113569A1 (en) 2021-04-22
IL250166A0 (en) 2017-03-30
CA2954840A1 (en) 2016-01-28
DK3172209T3 (da) 2021-02-22
EA039220B1 (ru) 2021-12-20
EA202191301A1 (ru) 2021-11-30
BR112017000953A2 (pt) 2017-11-14
US20190015418A1 (en) 2019-01-17
SG10201900648SA (en) 2019-02-27
AU2018207947A1 (en) 2018-08-09
NL301208I2 (nl) 2025-03-20
JP2017521469A (ja) 2017-08-03
SI3172209T1 (sl) 2021-03-31
CO2017000586A2 (es) 2017-06-20
KR102581121B1 (ko) 2023-09-21
CN115364061A (zh) 2022-11-22
PH12017500121A1 (en) 2017-05-29
AR101286A1 (es) 2016-12-07
NZ728089A (en) 2024-01-26
AU2015293539A1 (en) 2017-02-02
MX2017001177A (es) 2017-05-01
JP2020114852A (ja) 2020-07-30
US20250339440A1 (en) 2025-11-06
AU2020200912B2 (en) 2021-01-28
CN106714784A (zh) 2017-05-24
JP7002587B2 (ja) 2022-01-20
MX2021000595A (es) 2021-04-13
HUS2200054I1 (hu) 2023-01-28
ES2857523T3 (es) 2021-09-29
US20220249498A1 (en) 2022-08-11
WO2016012963A1 (en) 2016-01-28
HUE053346T2 (hu) 2021-06-28
JP6770946B2 (ja) 2020-10-21
PL3172209T3 (pl) 2021-06-14
TW202200148A (zh) 2022-01-01
JP2022046659A (ja) 2022-03-23
JO3618B1 (ar) 2020-08-27
TWI724993B (zh) 2021-04-21
MX379279B (es) 2025-03-11
US10085993B2 (en) 2018-10-02
EP3172209B1 (en) 2020-12-02
IL250166B (en) 2021-01-31
EP3848376A1 (en) 2021-07-14
GT201700007A (es) 2018-12-18
US12208101B2 (en) 2025-01-28
FR22C1058I2 (fr) 2023-11-17
TW201613595A (en) 2016-04-16
AU2020200912A1 (en) 2020-02-27
PE20170523A1 (es) 2017-05-17
US20170231997A1 (en) 2017-08-17
EP3172209A1 (en) 2017-05-31
PT3172209T (pt) 2021-02-11
NO2022058I1 (no) 2022-12-16

Similar Documents

Publication Publication Date Title
US12208101B2 (en) Tablet formulation of 2-fluoro-n-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide
JP6730978B2 (ja) 固形製剤
US8883777B2 (en) Compositions controlling pH range of release and/or release rate
EP2359816A1 (en) Aripiprazole formulations
HK40049437A (en) Tablet formulation of a c-met inhibitor
HK1231863A1 (en) Tablet formulation of 2-fluoro-n-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide
HK1231863B (en) Tablet formulation of 2-fluoro-n-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide
JP2020090484A (ja) エルロチニブを有効成分とする医薬錠剤
BR112017000953B1 (pt) Comprimido compreendendo 2-flúor-n-metil-4-[7-(quinolin6-il-metil) imidazo[1,2-b][1,2,4]triazin-2-il]benzamida
JP2020075924A (ja) エルロチニブを有効成分とする医薬錠剤
JP6739275B2 (ja) ゲフィチニブを有効成分とする医薬組成物
JP2020090456A (ja) エルロチニブを有効成分とする医薬錠剤
WO2022029798A1 (en) Pharmaceutical compositions comprising ribociclib

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20230918

Application number text: 1020177004939

Filing date: 20170222

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20231026

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20240602

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20231026

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I